

This is a repository copy of Estimating the costs of specialised care:updated analysis using data for 2009/10. Report to the Department of Health.

White Rose Research Online URL for this paper: https://eprints.whiterose.ac.uk/136686/

Version: Published Version

Monograph:

Daidone, S. and Street, A.D. orcid.org/0000-0002-2540-0364 (2011) Estimating the costs of specialised care:updated analysis using data for 2009/10. Report to the Department of Health. Working Paper. CHE Research Paper . Centre for Health Economics, University of York , York, UK.

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



THE UNIVERSITY of York





Estimating the Costs of Specialised Care: Updated Analysis Using Data for 2009/10

CHE Research Paper 71

| Estimating the Costs of Specialised Care |
|---|
| Updated Analysis Using Data for 2009/10 |

Silvio Daidone Andrew Street

Centre for Health Economics, University of York, UK

December 2011

Background to series

CHE Discussion Papers (DPs) began publication in 1983 as a means of making current research material more widely available to health economists and other potential users. So as to speed up the dissemination process, papers were originally published by CHE and distributed by post to a worldwide readership.

The CHE Research Paper series takes over that function and provides access to current research output via web-based publication, although hard copy will continue to be available (but subject to charge).

Acknowledgements

We would like to thank Sam Alderson, Jake Gommon, Eileen Robertson, and members of the Department of Health's analytical sub-group for Payment by Results. This is an independent report commissioned and funded by the Policy Research Programme in the Department of Health from the Economics of Social and Health Care Research Unit (ESHCRU). ESHCRU is a joint collaboration between the University of York, London School of Economics and University of Kent. The views expressed are those of the authors and may not reflect those of the funder.

Disclaimer

Papers published in the CHE Research Paper (RP) series are intended as a contribution to current research. Work and ideas reported in RPs may not always represent the final position and as such may sometimes need to be treated as work in progress. The material and views expressed in RPs are solely those of the authors and should not be interpreted as representing the collective views of CHE research staff or their research funders.

Further copies

Copies of this paper are freely available to download from the CHE website www.york.ac.uk/che/publications/ Access to downloaded material is provided on the understanding that it is intended for personal use. Copies of downloaded papers may be distributed to third-parties subject to the proviso that the CHE publication source is properly acknowledged and that such distribution is not subject to any payment.

Printed copies are available on request at a charge of £5.00 per copy. Please contact the CHE Publications Office, email che-pub@york.ac.uk, telephone 01904 321458 for further details.

Centre for Health Economics Alcuin College University of York York, UK www.york.ac.uk/che

Contents

| Execut | ive summary | ii |
|--------|--|----|
| 1. In | troduction | 1 |
| 2. Da | ata | 2 |
| 2.1 | Identifying whether a patient received specialised care | 2 |
| 2.2 | Mapping of reference costs to HES records | 2 |
| 2.3 | Assessing the cost of provider spells | 2 |
| 2.4 | Selection of the analytical sample | 3 |
| 3. Es | stimation models | 5 |
| 3.1 | Estimating the additional costs of specialised care | 5 |
| 3.2 | Sensitivity analyses | 5 |
| 3.3 | Estimating the additional costs of being transferred between hospitals | 6 |
| 4. De | escriptive statistics | 7 |
| 5. R | esults | 9 |
| 5.1 | Additional costs of specialist care | 9 |
| 5.2 | Sensitivity analyses | 11 |
| 5.3 | Transfers between providers | 12 |
| 6. C | onclusion | 14 |
| 7. R | eferences | 15 |
| Append | xib | 16 |
| | | |

Executive summary

Overview

Payment by Results is predicated on the assumption that patients allocated to the same Healthcare Resource Group (HRG) are equally costly to treat. This may be untrue for some patients, such as those who receive specialised care or who are transferred between hospitals. We assess whether and by how much such patients have higher costs than those allocated to the same HRG. Hospitals that treat such patients might be paid a top-up to the HRG tariff to reflect these higher costs.

Data and methods

We combine Hospital Episode Statistics data for all NHS patients treated in England during 2009/10 with cost data reported by all English hospitals. Our analytical sample consists of almost 13 million patients (provider spells), of whom 1.5 million received some form of specialised care and 620,000 were transferred.

We estimate econometric models to explore why costs vary from among patients. Our explanatory variables include: (i) the type of specialised care received, if any; (ii) whether or not the patient was transferred between hospitals; (iii) a range of other patient characteristics; and (iv) the hospital in which the patient was treated. We perform a range of sensitivity analyses.

Additional costs of specialist care

In general, results are stable between 2008/9 and 2009/10 and are consistent across model specifications. The main points are of note:

- Sixteen of the specialised markers are insignificant, meaning that patients that receive these
 types of specialised care do not have significantly higher costs than other patients allocated to
 the same HRG.
- For five of the markers, patients who received this type of specialised care had higher costs than those allocated to the same HRG who did not. The numbers of patients and the percentage increase in costs associated with specialised care are:
 - cancer (n=11,907, 24%)
 - infectious disease (n=2,246, 37%)
 - cystic fibrosis (n=101,770, 33%)
 - colorectal (n=7,355, 11%)
 - children (n=131,657, 20%).
- Five specialised markers (spinal, neurosciences, rheumatology, vascular diseases, orthopaedics) that were significant (*p*<0.01) in 2008/9, are either less significant (*p*<0.05) or insignificant in 2009/10. This appears to be due primarily to greater polarisation among providers in their reported costs.
- Results for the pain management specialised marker differ markedly from one year to the next. This is related to the increase in the number of patients defined as having this specialised marker and to changes in their cost distribution.

Patient transfers

We find that patients who were transferred between hospitals have significantly higher costs than those who do not. A reimbursement policy based on this evidence would have to consider the practical implications of redistributing resources across hospitals to reflect patient flows and any consequent changes to hospital behaviour.

1. Introduction

We were commissioned by the Department of Health's Payment by Results (PbR) team to use 2009/10 data update the analysis we performed using 2008/9 data to estimate the marginal costs of providing specialised care (Daidone and Street, 2011). The objectives of the original work were to investigate:

- 1. Whether the costs associated with specialised activity are significantly different from non-specialised activity within the same HRG;
- 2. Whether any differences in costs between specialised and non-specialised activity are due to differences in productive efficiency.

The objective of the update is:

- 1. To see whether the results obtained on the 2008-09 data are robust to 2009-10 data.
- 2. To investigate whether there is a case for differentiating payment on the basis of marginal cost differences arising when patients transferred between providers.

In the next section we describe various data issues, including how patients are identified as having received specialised care, how proxy patient-level costs are linked to HES records, and how the analytical sample is determined. In section three, we summarise the estimation models used to assess the marginal costs associated with receipt of specialised care and whether or not the patient was transferred between providers. Following a summary of descriptive statistics (section four), results are presented in section five for a variety of modelling choices. Estimates for 2009/10 are also compared to those derived from analysis of 2008/9 data.

2. Data

There are four major issues regarding the data that need to be addressed:

- How to determine whether or not a patient received specialised care;
- How to assign costs to each patient record in the Hospital Episode Statistics;
- How to determine the cost of a provider spell for those patients who have multiple consultant episodes;
- How to arrive at an analytical sample.

2.1 Identifying whether a patient received specialised care

Information in each patient's first diagnostic and procedural fields is examined to ascertain whether or not specialised care was received. A patient is assigned a specialised care marker if:

- One of the ICD10 in the primary diagnosis field or one of the OPCS codes^a in any of the
 procedure fields designated in the Specialised Services National Definition Set (SSNDS)
 is present in their HES record (an individual might have more than one marker) (NHS
 Specialised Services, 2010);
- They were treated at an eligible provider, because non-eligible providers should not be providing specialised services.

Specialised activity may not necessarily be more costly or complex, since the SSNDS defines activity as specialised if it requires a planning population of over 1 million people, without any specific relation to resource use.

2.2 Mapping of reference costs to HES records

To assign patient-level costs we follow the cascade procedure implemented with 2008-09 data, where each episode in HES is linked to the reference cost database based on: i) the hospital in which the patient is treated, ii) the HRG where the patient is categorized, iii) the type of admission — day case/elective/non-elective, and iv) the type of specialty. Further for elective and non-elective cases, when the length of stay goes beyond HRG specific trimpoints, we add the hospital's excess *per diem* cost for each additional day.

The matching between HES and RC databases has slightly improved with respect to the previous year's analysis. This is driven mainly by ensuring consistent coding of specialty in the HES and Reference Cost data by Great Ormond Street Hospital. This allowed a move from a 10% to 90% match of this provider's data.

2.3 Assessing the cost of provider spells

Each observation in HES comprises a Finished Consultant Episode (FCE), measuring the time the patient spends under the care of a particular consultant. As in 2008-09, 91% of patients remain under the care of a single consultant during their entire hospital stay. The remainder are cared for by more than one consultant, most usually because they are transferred from one specialty to another. We track the consultant episodes pertaining to each individual patient, allowing us to construct a provider spell for each patient, measuring the time from admission to discharge.

Multi-episode spells are likely to be more costly than single-episode spells, but there is no agreed method for determining the additional cost. In our previous report we found that estimation results were not sensitive to whether the cost of multi-episode spells was based on the Sum, Maximum or First of the costs of the constituent FCEs. Consequently, in the analysis that follows, the cost of a provider spell is calculated as the Sum of the cost of each FCE comprising the patient's spell in hospital.

^a ICD10: International Statistical Classification of Diseases and Related Health Problems 10th Revision; OPCS: Office for Population Censuses and Surveys Classification of Surgical Operations and Procedures

Irrespective of how costs are defined, patients that receive specialised care appear to have higher costs than those who do not, as can be seen in Table 1. The questions then are:

- Do cost differentials vary according to the particular type of specialised care that is provided?
- Are these higher costs due solely to the receipt of specialised care or are they (at least partially) related to the hospital in which care was provided?

Table 1: Mean (SD) costs by type of activity

| | 20 | 008-2009 | | 20 | 009-2010 | |
|------|----------|----------|---------|----------|----------|---------|
| | NOT SPEC | SPEC | ТОТ | NOT SPEC | SPEC | ТОТ |
| Sum | 1,385 | 1,884 | 1,436 | 1,452 | 2,057 | 1,521 |
| | (2,079) | (3,790) | (2,320) | (2371) | (4054) | (2625) |
| Max | 1,219 | 1,673 | 1,265 | 1,272 | 1,854 | 1,338 |
| | (1,730) | (3,210) | (1,940) | (1987) | (3536) | (2226) |
| Epi1 | 1,142 | 1,540 | 1,183 | 1,189 | 1,727 | 1,251 |
| | (1,587) | (2,929) | (1,777) | (1825) | 3282) | (2051) |

2.4 Selection of the analytical sample

From an initial sample of 18.1m HES episodes, our analytical sample is reduced to 14.5m episodes (and 12.9m spells) for the following reasons:

- We consider only those patients treated in NHS acute hospitals. Hence, patients treated in mental health, ambulance and primary care trusts and private providers are excluded;
- Duplicate HES records, those showing data inconsistencies and those missing key fields (eg epistart or epiend) are dropped;
- Some observations are excluded either because the reference costs for some hospitals could not be matched to HES records, because of miscoding of one of the variables used for mapping as described in section 2.2 (this is especially so for some renal dialysis, mental health, cystic fibrosis records); or they are unbundled services; or they are excluded from reference costs (eg intermediate care, well babies);^b
- We excluded those episodes with a length of stay in excess of 365 days.

In Table 2 we report how we reduced the full HES dataset to our analytical sample. Improvements in coding of data have allowed us to retain more of the data than in the previous years, with 80% of the full set of HES observations included in the 2009/10 analysis, up from 78% in the previous year.

_

^b See Department of Health (2009,2010)

Table 2: Eligibility and selection criterion

| | 2008 | 3/9 | 2009 | /10 |
|---|------------|------------|------------|------------|
| | | # episodes | | # episodes |
| Step | # episodes | dropped | # episodes | dropped |
| | | | | |
| Starting observations | 17,411,542 | | 18,126,831 | |
| Acute care trusts only | | 425,179 | | 470,272 |
| | 16,986,363 | | 17,656,559 | |
| Duplicates and inconsistent coding | | 852,326 | | 908,904 |
| | 16,134,037 | | 16,747,655 | |
| Unmatched reference cost | | 2,502,599 | | 2,189,667 |
| | 13,631,438 | | 14,557,988 | |
| Unmatched trimpoint and excess bed days | | | | |
| or zero cost per day | | 57,678 | | 31,451 |
| Total episodes | 13,573,760 | 3,837,782 | 14,526,537 | 3,600,294 |
| Total spells | 12,154,599 | | 12,971,384 | |

In Table 11 (see appendix) we provide details for each provider under the following columns:

- Totactivity: the total number of episodes reported in HES after eliminating duplicates and inconsistencies.
- Norefcost: the number of provider episodes with unmatched costs.
- Finalepi and finalspell: the number of episodes and spells used for the econometric analysis.
- %MISS and %SPEC: the percentage of missing episodes and the percentage of episodes with specialised care markers.

3. Estimation models

3.1 Estimating the additional costs of specialised care

As in our previous report (Daidone and Street, 2011), we define our dependent variable as the patient's standardised cost $y_{ik} = \frac{c_{ihk}}{\hat{c}_h}$ where c_{ihk} is the cost of patient i in HRG h in hospital k and \hat{c}_h is the national average cost of all patients allocated to HRG h.

If no account is taken of the possibility that costs may be partly related to the hospital in which care is provided, the marginal costs associated with receipt of specialised care are estimated by regressing each patient's standardised cost against the set (n=1...N) of specialised care markers (S) indicating the type of specialised care received (if any). The model takes the form:

$$y_i = \propto + \sum_{n=1}^{N} \beta_n S_{ni} + \varepsilon_i \tag{EQ1}$$

where β are the parameters to be estimated: if positive and significant, a patient with the specialist care marker has higher costs than do other patients allocated to the same HRG. ε_i captures random error.

As we have previously argued, this model fails to recognise that costs may be driven partly by the hospital in which the patient is treated. This can be examined by specifying a hierarchical model of the form:

$$y_{ik} = \propto + \sum_{n=1}^{N} \beta_n S_{nik} + u_k + v_{ik}$$
 (EQ2)

This is a multi-level model that recognises that patients (i=1...l) are clustered within hospitals (k=1...l). u_k is the hospital random effect: patients treated in hospitals with higher effects have higher costs than those treated elsewhere. v_{ik} captures random measurement error. We argue that this is the preferred model on which top-up payments should be made as it identifies the additional costs associated with receipt of specialised care, after controlling for the influence on costs of the hospital where treatment was provided.

The models are estimated using both ordinary least squares (OLS) and as a generalised linear model (GLM), and results are shown for both specifications.

3.2 Sensitivity analyses

We consider the sensitivity of estimates derived from applying equation 2 to:

- Analysing costs in their original form;
- Exclusion from the analysis of patients in HRGs in which everyone receives specialised care; and
- Dropping the requirement that specialised care is defined as being provided in eligible providers only.

Costs in original units

As an extension to the previous year's analysis, we now explore results when costs are not standardised to the national average. This involves incorporating additional explanatory variables that capture information about the HRG to which each patient is allocated. In this way we still account for the HRG to which patients are allocated by incorporating two additional variables, namely \hat{c}_h the national average cost of all patients allocated to HRG h and \tilde{c}_h the standard deviation in cost of all patients allocated to HRG h. This model does not risk the possibility of endogeneity that occurs when the independent variable is correlated with the error term. The model is specified as:

$$c_{ik} = \propto +\delta_1 \hat{c}_h + \delta_2 \tilde{c}_h + \sum_{n=1}^N \beta_n S_{nik} + u_k + v_{ik}$$
 (EQ3)

Fully specialised HRGs

The construction of some HRGs means that everyone allocated to them receives specialised care. This is because the HRG itself is defined using the ICD or OPCS codes that are also used as indicators of specialised care. Conversely, some HRGs contain no patients that received specialised care. The HRGs where the former situation occurs are listed in Table 10 in the appendix.

Estimates might be biased by including in the analysis HRGs exclusively populated by patients who did receive specialised services. This is because for these HRGs there is no comparative reference group of patients allocated to the HRG who did not receive specialised care. This makes it impossible to calculate the differential costs associated with receipt of specialised care for patients allocated to these HRGs. The extent to which this introduces bias to the estimates of the specialised care marker depends on how representative patients allocated to these fully specialised HRGs are of all patients who receive the particular type of specialised care in question.

Dropping patients in those HRGs in which everyone is identified as having received specialised care and those HRGs in which no-one is identified as having received specialised care reduces the analytical sample by 1.9% (256,861 spells).

Eligible providers

Some hospitals are or have been designated by the Department of Health as eligible for top-up payments for some specialised services. As would be expected, hospitals which are or have been eligible for top-ups now or in the past undertake more specialised spells than do other hospitals.

As described in section 2.1, a patient is defined as receiving specialised care if one of the SSNDS ICD10 or OPCS codes was present in their medical record *and* they were treated at an eligible provider. We assess the sensitivity of results to relaxation of the condition that specialised services have to be delivered by eligible providers, so that the marker is assigned on the basis of the ICD10 or OPCS codes alone.

3.3 Estimating the additional costs of being transferred between hospitals

We also assess whether patients who are transferred between institutions have higher costs than other patients. This involves adding a vector of additional patient characteristics to equation 1, among which are dummy variables indicating the type of transfer experienced by the patient, if any. The model is specified as:

$$y_{ik} = \propto + \sum_{n=1}^{N} \beta_n S_{nik} + \sum_{m=1}^{M} \gamma_m X_{mik} + u_k + v_{ik}$$
 (EQ4)

where X is the set (m=1...M) of patient characteristics and γ is the vector of parameters to be estimated. If positive and significant, patients with the particular characteristics have higher costs than those who do not.

Among this set of variables are four which describe the type of transfer, if one took place. Patients admitted as transfers are coded 51, 52 and 53 in the admission source field of their HES record; analogously, those transferred from hospital to other institutions are coded 51, 52 and 53 in the discharge destination field of their HES record (NHS Information Centre, 2011). We define four dummy variables:

- Transfer from an eligible provider, whereby the patient was admitted to hospital having been transferred from a provider that is eligible for specialised payments (tr in el);
- Transfer from a non-eligible provider, whereby the patient was admitted to hospital having been transferred from a provider that is not eligible for specialised payments (tr in nonel);
- Transfer to an eligible provider, whereby the patient is transferred to a provider that is eligible for specialised payments (tr out el);
- Transfer to a non-eligible provider, whereby the patient is transferred to a provider that is not eligible for specialised payments (trout nonel).

4. Descriptive statistics

In 2009/10, for approximately 1.5m (11.4%) of patients it was indicated that some kind of specialised care was delivered as part of the treatment package. Table 3 reports the number of patients with particular conditions who receive specialised services and are included in the analysis. For a few specialised services, provision has declined compared to 2008/9 – notably cancer (-2,000), liver (-2,600) and respiratory (-3,500). For others, more patients received specialised care than in the previous year. Most noticeable were the increases for renal (+150,000), cystic fibrosis (+10,000), cleft lip (+15,000) and children (+27,000). For children, much of the increase is due to inclusion of a greater proportion of data from Great Ormond Street. For the vast majority of patients, just one specialised service was delivered but more than 35,000 patients received more than one specialised service.

Table 3: Number of patients receiving specialised services for whom costs are available

| Service | 2008/9 | 2009/10 | Service | 2008/9 | 2009/10 |
|---------------------|---------|---------|---------------------|---------|---------|
| Cancer | 14,035 | 11,907 | Dermatology | 10,790 | 12,298 |
| BMT | 1,050 | 364 | Rheumatology | 358 | 338 |
| Haemophilia | 146 | 153 | Endocrinology | 7,028 | 7,306 |
| Women | 22,551 | 24,389 | Respiratory | 71,824 | 68,374 |
| Spinal | 2,167 | 2,507 | Vascular diseases | 801 | 1,215 |
| Neurosciences | 23,848 | 26,204 | Pain Management | 753 | 1,266 |
| Cystic fibrosis | 91,868 | 101,770 | Ear surgery | 1,704 | 1,655 |
| Renal | 360,957 | 510,847 | Colorectal | 6,838 | 7,355 |
| Intestinal failure | 2,380 | 2,246 | Orthopaedic | 3,671 | 4,207 |
| Cardiology | 89,127 | 90,381 | Morbid obesity | 7,905 | 11,458 |
| Cleft lip | 222,939 | 238,141 | Metabolic disorders | 3,182 | 3,236 |
| Infectious diseases | 2,203 | 2,039 | Ophthalmology | 6,345 | 7,006 |
| Liver | 14,807 | 12,244 | Haemoglobinopathy | 146,403 | 159,788 |
| Children | 104,764 | 131,657 | More than 1 service | 32,311 | 35,972 |

In Table 4 we provide some descriptive statistics of the explanatory variables used to describe patient characteristics (ie X_m in equation 4). Patients receiving specialised services are more likely to be male, younger (probably mainly because infants are more likely to require specialised care, 16% of them at birth), and to have been transferred between hospitals. Notably, there are no major differences in the proportions of patients with each particular characteristic between the two years of data. Variable definitions are provided in Table 14 in the appendix.

Table 4: Descriptive statistics of explanatory variables (mean above, st.dev. below)

| | | 2008/9 | | | 2009/10 | |
|--------------|---------------------|---------------------|--------------------|---------------------|--------------------|---------------------|
| | NOT SPEC | SPEC | ТОТ | NOT SPEC | SPEC | ТОТ |
| female1 | 0.574 | 0.445 | 0.56 | 0.577 | 0.442 | 0.558 |
| | (0.495) | (0.497) | (0.496) | (0.495) | (0.497) | (0.497) |
| age | 51.61 | 49.94 | 51.44 | 51.56 | 50.42 | 51.43 |
| | (24.24) | (25.7) | (24.4) | (24.49) | (25.76) | (24.64) |
| urban1 | 0.818 | 0.817 | 0.818 | 0.818 | 0.827 | 0.819 |
| | (0.386) | (0.387) | (0.386) | (0.386) | (0.378) | (0.385) |
| episodes | 1.118 | 1.108 | 1.117 | 1.122 | 1.102 | 1.12 |
| | (0.426) | (0.545) | (0.440) | (0.442) | (0.546) | (0.455) |
| emerg | 0.383 | 0.159 | 0.36 | 0.396 | 0.145 | 0.367 |
| | (0.486) | (0.366) | (0.48) | (0.489) | (0.352) | (0.482) |
| die | 0.0155 | 0.0181 | 0.0158 | 0.0143 | 0.0153 | 0.0145 |
| | (0.124) | (0.133) | (0.125) | (0.119) | (0.123) | (0.119) |
| tr_in_el | 0.0000394 | 0.00016 | 5.20E-05 | 0.0000493 | 0.000158 | 0.0000617 |
| | (0.00628) | (0.0128) | (0.0072) | (0.00702) | (0.0126) | (0.00785) |
| tr_in_nonel | 0.0265 | 0.0414 | 0.028 | 0.03 | 0.0376 | 0.0308 |
| | (0.161) | (0.199) | (0.165) | (0.17) | (0.19) | (0.173) |
| tr_out_el | 0.00501 | 0.00491 | 0.005 | 0.00532 | 0.00498 | 0.00528 |
| | (0.0706) | (0.0699) | (0.0705) | (0.0728) | (0.0704) | (0.0725) |
| tr_out_nonel | 0.0113 | 0.0135 | 0.0116 | 0.0115 | 0.0128 | 0.0117 |
| | (0.106) | (0.115) | (0.107) | (0.107) | (0.112) | (0.107) |
| pregnancy | 0.104 | 0.00528 | 0.0941 | 0.107 | 0.0039 | 0.0951 |
| | (0.306) | (0.0725) | (0.292) | (0.309) | (0.0623) | (0.293) |
| drug | 0.00324 | 0.00203 | 0.00312 | 0.00355 | 0.00211 | 0.00339 |
| | (0.0568) | (0.045) | (0.056) | (0.0595) | (0.0459) | (0.0581) |
| alcohol | 0.017 | 0.00732 | 0.016 | 0.0198 | 0.00692 | 0.0183 |
| | (0.129) | (0.0852) | (0.125) | (0.139) | (0.0829) | (0.134) |
| smoke | 0.0369 | 0.0348 | 0.0367 | 0.0468 | 0.0367 | 0.0456 |
| | (0.189) | (0.183) | (0.188) | (0.211) | (0.188) | (0.209) |
| obesity | 0.0072 | 0.014 | 0.00791 | 0.00993 | 0.0154 | 0.0106 |
| | (0.0845) | (0.118) | (0.089) | (0.0991) | (0.123) | (0.102) |
| allergy | 0.0276 | 0.0191 | 0.0267 | 0.0328 | 0.0201 | 0.0313 |
| | (0.164) | (0.137) | (0.161) | (0.178) | (0.14) | (0.174) |
| diabetes | 0.0785 | 0.0626 | 0.0769 | 0.0869 | 0.0603 | 0.0838 |
| 1 | (0.269) | (0.242) | (0.266) | (0.282) | (0.238) | (0.277) |
| hypertens | 0.171 | 0.121 | 0.165 | 0.192 | 0.117 | 0.184 |
| 1 | (0.376) | (0.326) | (0.372) | (0.394) | (0.322) | (0.387) |
| haemorr | 0.00393 | 0.00899 | 0.00445 | 0.00452 | 0.00781 | 0.00489 |
| 1-1-4-31- | (0.0626) | (0.0944) | (0.067) | (0.0671) | (0.088) | (0.0698) |
| histdis | 0.108 | 0.0866 | 0.106 | 0.124 | 0.0862 | 0.119 |
| wielrfoet | (90.31) 0.00729 | (0.281) 0.00265 | (0.307) 0.00681 | (0.329) 0.00907 | (0.281) 0.0032 | (0.324) 0.0084 |
| riskfact | | | | | | |
| 20.0000016 | (0.0851) | (0.0514) | (0.082) | (0.0948) | (0.0565) 0.0522 | (0.0913) |
| congmalf | 0.0113 | 0.0487 | 0.0151 | 0.0124 | | 0.0169 |
| rielz phys | (0.106) 0.000643 | (0.215) 0.00119 | (0.122) 0.0007 | (0.111) 0.000675 | (0.222) 0.00125 | (0.129) 0.000741 |
| risk_phys | | | | (0.026) | (0.00125) | |
| riek nevece | (0.0254) 0.00384 | (0.0345) 0.00157 | (0.027) 0.00361 | 0.00447 | 0.00148 | (0.0272) 0.00413 |
| risk_psysoc | | | | | | |
| | (0.0619) | (0.0395) | (0.060) | (0.0667) | (0.0384) | (0.0641) |

5. Results

5.1 Additional costs of specialist care

We have estimated various equations and explored the sensitivity of estimates to a range of modelling choices. The cost of a provider spell is calculated as the sum of the cost of the constituent episodes and each patient is assigned a specialist marker if one of the SSNDS ICD10 or OPCS codes appears in their record and they were treated at an eligible provider. In this section we focus on the estimates associated with the specialised markers. Rather than reporting the coefficients, we report the predicted percentage increase in costs for specialised services calculated as described in our earlier report (Daidone and Street, 2011). The specialised markers where estimates are statistically significant appear in bold if p<0.01 and underlined if p<0.05.

Table 5: Equations 1 and 2 on standardised dependent variable

| | | Equation | on 1 | | Equation 2 | | | |
|---------------------|---------|----------|---------|--------|------------|--------|----------------|--------|
| | 2008-20 | - | 2009-20 |)10 | 2008-20 | - | 2009-20 | 010 |
| | OLS | GLM | OLS | GLM | OLS | GLM | OLS | GLM |
| Cancer | 0.217 | 0.218 | 0.307 | 0.313 | 0.184 | 0.185 | 0.242 | 0.244 |
| BMT | -0.055 | -0.035 | -0.037 | -0.037 | -0.105 | -0.086 | - <u>0.297</u> | -0.222 |
| Haemophilia | -0.089 | -0.090 | -0.132 | -0.129 | -0.144 | -0.142 | -0.159 | -0.157 |
| Womens | -0.003 | -0.002 | 0.063 | 0.061 | -0.019 | -0.018 | 0.046 | 0.046 |
| Spinal | 0.323 | 0.336 | 0.140 | 0.154 | 0.276 | 0.279 | -0.115 | -0.084 |
| Neurosciences | 0.279 | 0.276 | 0.280 | 0.275 | 0.229 | 0.225 | 0.171 | 0.171 |
| Cystic Fibrosis | 0.397 | 0.394 | 0.357 | 0.354 | 0.379 | 0.380 | 0.331 | 0.335 |
| Renal | -0.112 | -0.114 | 0.228 | 0.230 | -0.112 | -0.112 | 0.175 | 0.180 |
| Intestinal Failure | -0.007 | -0.004 | -0.003 | -0.002 | 0.002 | 0.004 | 0.008 | 0.009 |
| Cardiology | 0.138 | 0.138 | 0.118 | 0.119 | 0.001 | 0.000 | 0.007 | 0.011 |
| CleftLip | -0.017 | -0.018 | 0.034 | 0.035 | -0.042 | -0.044 | 0.022 | 0.023 |
| Infectious Diseaes | 0.264 | 0.240 | 0.408 | 0.393 | 0.213 | 0.189 | 0.379 | 0.372 |
| Liver | 0.098 | 0.099 | 0.125 | 0.128 | 0.075 | 0.076 | 0.003 | 0.018 |
| Children | 0.280 | 0.278 | 0.301 | 0.302 | 0.200 | 0.193 | 0.215 | 0.204 |
| Dermatology | 0.009 | 0.009 | -0.003 | -0.007 | -0.009 | -0.009 | -0.019 | -0.022 |
| Rheumatology | 0.183 | 0.184 | 0.331 | 0.337 | 0.130 | 0.130 | 0.102 | 0.089 |
| Endocrinology | 0.045 | 0.041 | 0.061 | 0.057 | -0.007 | -0.010 | -0.014 | -0.011 |
| Respiratory | 0.046 | 0.041 | 0.078 | 0.072 | -0.038 | -0.041 | 0.001 | -0.002 |
| Vascular Diseases | 0.246 | 0.241 | 0.343 | 0.323 | 0.211 | 0.203 | 0.218 | 0.198 |
| Pain Management | 0.188 | 0.157 | 2.255 | 2.283 | 0.190 | 0.169 | 2.129 | 2.101 |
| EarSurgery | 0.057 | 0.058 | 0.082 | 0.086 | -0.001 | -0.001 | -0.111 | -0.078 |
| Colorectal | 0.214 | 0.214 | 0.129 | 0.129 | 0.211 | 0.214 | 0.112 | 0.114 |
| Orthopaedic | 0.244 | 0.238 | 0.164 | 0.161 | 0.213 | 0.207 | 0.004 | 0.011 |
| Morbid Obesity | -0.027 | -0.027 | -0.068 | -0.068 | -0.008 | -0.007 | -0.068 | -0.071 |
| Metabolic Disorders | 0.022 | 0.011 | 0.427 | 0.430 | -0.016 | -0.021 | 0.312 | 0.295 |
| Ophthalmology | 0.080 | 0.076 | 0.074 | 0.069 | 0.057 | 0.055 | 0.057 | 0.053 |
| Haemoglobinopathy | 0.013 | 0.009 | 0.065 | 0.066 | 0.003 | 0.000 | 0.052 | 0.056 |

Notes: Bold figures 1% significant, underlined figures 5%

Table 5 shows estimates of additional costs associated with receipt of specialised care from applying equations 1 and 2, estimated using OLS and GLM models and for the two years of data. The estimates are not sensitive to the choice of OLS and GLM. As to year-on-year comparisons, estimates are very similar in most of the cases, both in terms of magnitude and statistical significance. This is despite the fact that the reference populations have changed, as they are composed of two entirely different sets of patients.

Focussing on equation 2, the main points are the following:

- Sixteen of the specialised markers are insignificant, across both the OLS and GLM specifications and for the two years of data. This means that patients that receive specialised care of the nature indicated by the specialised marker do not have significantly higher costs than other patients allocated to the same HRG.
- For five of the markers, patients who received this type of specialised care had higher costs than those allocated to the same HRG who did not. These markers are cancer,

cystic fibrosis, infectious disease, children and colorectal. The significance (p<0.01) of these markers holds across specifications and over time. The estimates of the amount by which costs are higher do vary from one year to the next though. The estimates are higher for cancer (from 18% to 24%) and infectious disease (21% to 37%) and are lower for cystic fibrosis (38% to 33%) and colorectal (21% to 11%). The estimates are unchanged for children's specialised services (20%).

- Five specialised markers (spinal, neurosciences, rheumatology, vascular diseases, orthopaedics) that were significant in 2008/9, are no longer significant at *p*<0.01, though results remain significant at *p*<0.05 for neurosciences and vascular diseases (under the GLM specification). Compare these estimates to those derived from applying equation 1. We find that, with the exception of the marker for spinal services, the other four specialised markers are significant in 2009/10 provided that no account is taken of the hospital in which patients are treated. This suggests greater polarisation in 2009/10 among providers in the costs of treating patients allocated to the HRGs in which these specialised markers tend to appear.
- In Table 6 we report the number of hospitals where mean costs decrease or increase by more than 0.5 standard deviations of the mean across all patients in 2009/10. Polarisation is evident if there are large reductions in cost for some providers and large increases for others.
- Consider first the specialised care for cystic fibrosis. For these services, no hospital reported large decreases in cost, and few very experienced increases. The estimates reported in Table 5 for this specialist marker are quite stable across specifications and over time.
- In contrast, Table 6 shows that mean hospital costs changed considerably for a sizeable large numbers of hospitals providing specialised care in rheumatology, vascular diseases and orthopaedics. This variance across hospitals is captured by the hospital effect, rather than by the specialist marker which appears non-significant in Eqn 2 for 2009/10 (Table 5).
- Polarisation in mean costs across hospitals is less extreme for specialised neurosciences care than for rheumatology, vascular diseases and orthopaedics. Consequently in 2009/10, the coefficient on this specialised marker remains significant in Eqn 2, albeit at a lower significance level.
- For specialised spinal care, there is little change from one year to the next in the location and shape of the overall distribution of costs for patients who received this form of specialised care. In contrast to 2008/9, the non-significance of this marker in 2009/10 is partly due to changes in costs for patients who did not receive specialised spinal care who are allocated to the same HRGs as patients who did and partly due to the handful of hospitals (5-6%) for which mean costs changed by +/- 0.5 standard deviations of the overall mean.

Table 6: Number (%) of hospitals in which mean costs vary from 2008/9 and 2009/10 by +/- 0.5SD of the underlying distribution

| | Decrease by < | 0.5SD | Increase by >0 | .5SD |
|-------------------|---------------|-------|----------------|------|
| Cystic fibrosis | 0 | 0% | 4 | 3% |
| Rheumatology | 10 | 15% | 16 | 25% |
| Vascular Diseases | 9 | 9% | 17 | 17% |
| Orthopaedics | 14 | 10% | 19 | 13% |
| Neurosciences | 4 | 3% | 5 | 3% |
| Spinal | 9 | 6% | 8 | 5% |

• Finally, returning to Table 5, the pain management marker was insignificant in 2008/9 but is remarkably so in 2009/10. This is explained partly by the 50% increase in the number of patients with this specialised marker Table 3) and by changes in the location and

shape of the cost distribution for these patients, the lower peak and longer tail in 2009/10 being most notable (figure 1). These changes are reflected in the dramatic change between the two years in the estimated coefficients associated with this specialised marker.




Figure 1: Kernel density estimation of specialised services costs

5.2 Sensitivity analyses

The OLS estimates for 2009/10 reported in Table 5 are reproduced in column 1 in Table 7 alongside estimates from the sensitivity analyses, namely:

- Analysing costs in their original form (EQ3, column 2);
- Exclusion from the analysis of patients in HRGs in which everyone receives specialised care (column 3); and
- Dropping the requirement that specialised care is defined as being provided in eligible providers only (column 4).

The main points of note are:

- For the majority of specialised care markers, the estimates are unchanged across all forms of sensitivity analysis. Twenty of the markers that were insignificant (p>0.01) under the original specification remain so under the three alternatives.
- The receipt of specialised cancer care is consistently estimated to increase costs by 24%.
- The magnitude and (sometimes) significance of the estimates for four of the markers are sensitive to whether costs are standardised (EQ2, column 1) or estimated in original units (EQ3, column 2). Estimates are higher if applying EQ3 for neurosciences (17% to 32%), cystic fibrosis (33% to 61%) and infectious diseases (38% to 49%). For pain management, the cost differential no longer appears significant.
- Results are not sensitive to dropping HRGs in which everyone is identified as having received specialised care and those HRGs in which no-one is identified as having received specialised care. The signs and, where significant, the magnitudes of the estimates reported in columns 1 and 3 are virtually identical. Interestingly, this is true even for cardiology, where a high proportion of HRGs are populated entirely by patients defined as having received specialised care (Table 10 in Appendix).

Table 7: Sensitivity analysis, equation 2 - 2009/2010

| | | 2009- | 2010 | |
|--------------------------|---------------|---------------------|----------------|--------------------------------|
| | (1) | (2) | (3) | (4) |
| | Standardised | Raw Dependent | 100% fully | No eligibility |
| | Dependent | Variable - equation | specialized | requirements |
| | Variable – | 3 | HRGs dropped - | equation 2 |
| | equation 2 | | equation 2 | |
| Cancer | 0.242 | 0.238 | 0.240 | 0.242 |
| BMT | <u>-0.297</u> | -0.366 | -0.347 | <u>-0.296</u> |
| Haemophilia | -0.159 | -0.120 | -0.162 | -0.160 |
| Womens | 0.046 | -0.005 | 0.046 | 0.046 |
| Spinal | -0.115 | 0.138 | -0.120 | -0.077 |
| Neurosciences | <u>0.171</u> | 0.315 | <u>0.166</u> | 0.151 |
| Cystic Fibrosis | 0.331 | 0.611 | 0.339 | 0.330 |
| Renal | 0.175 | 0.054 | 0.176 | 0.174 |
| Intestinal Failure | 0.008 | -0.007 | 0.009 | 0.008 |
| Cardiology | 0.007 | 0.065 | 0.008 | 0.016 |
| CleftLip | 0.022 | 0.014 | 0.022 | 0.021 |
| Infectious Diseases | 0.379 | 0.491 | 0.379 | 0.379 |
| Liver | 0.003 | 0.126 | -0.004 | 0.011 |
| Children | 0.215 | 0.211 | 0.223 | 0.102 |
| Dermatology | -0.019 | 0.002 | -0.024 | -0.021 |
| Rheumatology | 0.102 | 0.149 | 0.102 | 0.101 |
| Endocrinology | -0.014 | 0.028 | -0.016 | -0.014 |
| Respiratory | 0.001 | 0.089 | 0.014 | 0.029 |
| Vascular Diseases | 0.218 | <u>0.790</u> | 0.276 | 0.214 |
| Pain Management | 2.129 | 1.181 | 2.127 | 2.125 |
| EarSurgery | -0.111 | 0.141 | -0.036 | -0.113 |
| Colorectal | 0.112 | <u>0.127</u> | 0.112 | 0.111 |
| Orthopaedic | 0.004 | 0.112 | 0.003 | 0.003 |
| Morbid Obesity | -0.068 | -0.259 | -0.071 | -0.069 |
| Metabolic Disorders | 0.312 | -0.076 | 0.306 | 0.303 |
| Ophthalmology | 0.057 | 0.030 | 0.058 | 0.056 |
| <u>Haemoglobinopathy</u> | 0.052 | <u>0.053</u> | 0.053 | 0.053 |

Notes: Bold figures 1% significant, underlined figures 5%

- In the fourth column of Table 7 we present the effects for the specialist markers followed by the effects generated after relaxing the condition that specialised services have to be delivered only by eligible providers. Again comparing these estimates with those in column 1, the results are generally not sensitive to whether or not specialised care is defined as being confined to eligible providers.
- There is, however, one notable exception: the cost increase associated with specialised children services is now estimated to amount to just 10%, rather than 22%. This would suggest that the cost of specialised children's care is lower in non-eligible than eligible providers.

5.3 Transfers between providers

Providers have raised the question of whether patients who are transferred between providers should receive a top-up and, if so, what value the top-up should take. In answering this we first evaluate how many patients are transferred and the marginal cost consequences of being transferred.

Table 8 provides details of the number of patients who were transferred into or from other institutions, according to whether or not their hospital was eligible for specialised top-ups and to whether or not they received specialised care. The proportion of patients who were transferred into hospital increased from 2.8% in 2008/9 to 3.1% in 2009/10. The proportion of patients transferred to other providers was 1.7% in both years.

Table 8: Number of spells with patients transferred

| | | | Numbe | r of spells | | |
|-------------------|----------|-----------|---------|-------------|----------|---------|
| | 2 | 2008-2009 | | | 2009-201 | 0 |
| Transfer type | Not Spec | Spec | Tot | Not Spec | Spec | Tot |
| From eligible | 445 | 216 | 661 | 567 | 233 | 800 |
| From non-eligible | 289,139 | 51,800 | 340,939 | 344,445 | 55,457 | 399,902 |
| To eligible | 54,609 | 6,153 | 60,762 | 61,203 | 7,345 | 68,548 |
| To non-eligible | 123,722 | 16,879 | 140,601 | 132,290 | 18,896 | 151,186 |

Those who were transferred have significantly higher costs than those who do not (Table 9). Patients transferred from non-eligible providers have costs 24% higher than those who do not (all else equal), and those transferred to other providers have 11-13% higher costs.

Table 9: Coefficient estimates of transfer variables, equation 4.

| | Co efficient estimates | | | |
|-------------------|------------------------|-----------|--|--|
| | 2008-2009 | 2009-2010 | | |
| From eligible | 0.008 | -0.061 | | |
| | (0.070) | (0.057) | | |
| From non-eligible | 0.16** | 0.235*** | | |
| | (0.071) | (0.040) | | |
| To eligible | 0.14*** | 0.132*** | | |
| | (0.016) | (0.017) | | |
| To non-eligible | 0.129*** | 0.110*** | | |
| | (0.020) | (0.015) | | |

Notes: standard errors in parentheses. *** 1% significant - ** 5% significant

Even though patients who are transferred have higher costs than those who do not, introducing topup payments to reflect this might not be straightforward, for two main reasons:

- First, in effect, any payment adjustment should reflect patient flows, with funding being redistributed from providers that transfer patients elsewhere to providers that admit them. This would be prohibitively costly to implement on a case-by-case basis, so probably the redistribution would have to be undertaken centrally and retrospectively.
- Second, payments of this nature might lead to changes in decisions about whether or not to transfer patients elsewhere. This may be no bad thing, but an evaluation of potential behavioural change might be required.

6. Conclusion

In general, results are stable from one year to the next and are consistent across model specifications. Of note are the following points:

- Sixteen of the specialised markers are insignificant, meaning that patients that receive
 these types of specialised care do not have significantly higher costs than other patients
 allocated to the same HRG.
- For five of the markers, patients who received this type of specialised care had higher costs than those allocated to the same HRG who did not. The numbers affected and the percentage increase in costs associated with each form of specialised care are:
 - cancer (n=11,907, 24%)
 - infectious disease (n=2,246, 37%)
 - cystic fibrosis (n=101,770, 33%)
 - colorectal (n=7,355, 11%)
 - children (n=131,657, 20%).
- Five specialised markers (spinal, neurosciences, rheumatology, vascular diseases, orthopaedics) that were significant (*p*<0.01) in 2008/9, are either less significant (*p*<0.05) or insignificant in 2009/10. This appears to be due primarily to greater polarisation among providers in their reported costs.
- Results for pain management marker differ markedly from one year to the next. This is
 related to the increase in the number of patients defined as having this specialised marker
 and to changes in the overall distribution of their costs.

We also find that, after controlling for whether or not they receive specialised care and for a range of other characteristics, patients who were transferred between hospitals have significantly higher costs than those who do not. This evidence is a necessary but not sufficient condition for introducing top-up payments for such patients. Any such policy would have to consider the practical implications of redistributing resources to reflect patient flows and any consequent changes to hospital behaviour toward patients who might be transferred.

7. References

Daidone S & Street A. 2011. *Estimating the costs of specialised care, CHE Research Paper 61: York,* Centre for Health Economics.

Department of Health. 2010. Reference Costs 2009-10, Collection Guidance Final

Department of Health 2009. Reference Costs 2008-09, Collection Guidance Final

NHS Information Centre (2011) "Data Dictionary: Inpatients" in HESonline - Hospital Episode Statistics, available at http://www.hesonline.nhs.uk

NHS Specialised Services (2010) Specialised Services National Definition Set (3rd edition) http://www.specialisedservices.nhs.uk/documents/index/document_category_id:26

Appendix

Table 10: Fully specialised HRGs

| hrg4 | Episodes | HRG description |
|----------------|------------|---|
| EA14Z | 11,467 | Coronary Artery Bypass Graft (First Time) |
| DZ18Z | 4,292 | Sleeping Disorders Affecting Breathing |
| EA17Z | 3,624 | Single Cardiac Valve Procedures |
| EA51Z | 3,170 | Coronary Artery Bypass Graft with valve replacement or repair |
| GC01B | 2,742 | Liver Failure Disorders without Interventions |
| LB29B | 2,532 | Urethra Major Open Procedures 18 years and under |
| AA28Z | 2,432 | Motor Neuron Disease |
| EA16Z | 2,403 | Coronary Artery Bypass Graft (First Time) with Percutaneous Coronary Intervention, Pacing, EP of RFA |
| FZ24D | 1,351 | Major Therapeutic Open or Endoscopic Procedures 18 years and under |
| EA20Z | 1,295 | Other Complex Cardiac Surgery and Re-do's |
| EA19Z | 1,087 | Single Cardiac Valve Procedures with Percutaneous Coronary Intervention, Pacing, EP or RFA |
| GC01A | 921 | Liver Failure Disorders with Interventions |
| SA26A | 857 | Peripheral Blood Stem Cell Transplant - Autologous 19 years and over |
| EA52Z | 856 | Repair or replacement of more than one heart valve |
| CZ26Z | 741 | Bone Anchored Hearing Aids |
| JC19U | 707 | Electrical and other invasive therapy 4 - 18 years and under |
| LB46Z | 693 | Live Donation of Kidney |
| EA26Z | 638 | Standard Congenital Surgery |
| CZ25Q | 633 | Cochlear Implants without CC |
| LA03A | 614 | Kidney Transplant 19 years and over from Live donor |
| SA14Z | 494 | Plasma Exchanges 2 to 9 |
| LA02A | 469 | Kidney Transplant 19 years and over from Cadaver Heart beating donor |
| DZ33Z | 433 | Hyperbaric Oxygen Treatment |
| EA23Z SA28A | 363 | Major Complex Congenital Surgery |
| DZ21G | 346 238 | Peripheral Blood Stem Cell Transplant - Allogeneic 19 years and older Chronic Obstructive Pulmonary Disease or Bronchitis with NIV without Intubation without CC |
| LA01A | 230 | Kidney Transplant 19 years and over from Cadaver non-Heart beating donor |
| SA19A | 229 | Bone Marrow Transplant - Autograft 19 years and over |
| CZ25N | 218 | Cochlear Implants with CC |
| HC09Z | 174 | Intradural Spine Intermediate 2 |
| SA15Z | 142 | Plasma Exchanges 10 to 19 |
| EA22Z | 129 | Other Complex Cardiac Surgery with Percutaneous Coronary Intervention, Pacing, EP or RFA |
| FZ01C | 116 | Complex Oesophageal Procedures 18 years and under |
| HC08Z | 103 | Intradural Spine Major 1 |
| DZ01Z | 89 | Lung Transplant |
| SA20A | 88 | Bone Marrow Transplant - Allogeneic Graft (Sibling) 19 years and over |
| EA02Z | 84 | Heart Transplant |
| EA43Z | 81 | Implantation of Prosthetic Heart or Ventricular Assist Device |
| SA26B | 50 | Peripheral Blood Stem Cell Transplant - Autologous 18 years and under |
| LA03B | 44 | Kidney Transplant 18 years and under from Live donor |
| LA02B | 42 | Kidney Transplant 18 years and under from Cadaver Heart beating donor |
| SA28B | 31 | Peripheral Blood Stem Cell Transplant - Allogeneic 18 years and under |
| SA20B | 30 | Bone Marrow Transplant - Allogeneic Graft (Sibling) 18 years and under |
| SA21B | 20 | Bone Marrow Transplant - Allogeneic Graft (Volunteer Unrelated Donor) 18 years and under |
| LA12A | 19 | Kidney pre-transplantation work-up of recipient 19 years and over |
| SA22A | 16 | Bone Marrow Transplant - Allogeneic Graft (Cord Blood) 19 years and over |
| LA11Z | 15 | Kidney pre-transplantation work-up of live donor |
| SA16Z | 13 | Plasma Exchanges 20 or more |
| WA01Y | 12 | Manifestations of HIV/AIDS without CC |
| SA19B | 11 | Bone Marrow Transplant - Autograft 18 years and under |
| WA01W | 10 | Manifestations of HIV/AIDS with CC |
| SA22B | 10 | Bone Marrow Transplant - Allogeneic Graft (Cord Blood) 18 years and under |
| GA01B | 9 | Hepatobiliary Transplant 2 to 17 years |
| GA01A | 6 | Hepatobiliary Transplant 1 year and under |
| LA10Z | 5 | Live Kidney donor screening |
| DZ46Z | 4 | Respiratory Muscle Strength Studies Kidney Transplant 18 years and under from Cadavar non-Heart heating donor |
| LA01B SA27A | 3 2 | Kidney Transplant 18 years and under from Cadaver non-Heart beating donor Peripheral Blood Stem Cell Transplant - Syngeneic 19 years and over |
| SA27A SA23A | 2 | Bone Marrow Transplant - Allogeneic Graft (Haplo-Identical) 19 years and over |
| SHLSH | Z | |
| DZ45Z | 1 | Lung Volume Studies |

Table 11: Provider Information

Key: **Totactivity**: the total number of episodes reported in HES after eliminating duplicates and inconsistencies. **Norefcost**: the number of provider episodes with unmatched costs. The two columns **finalepi** and **finalspell** represent respectively the number of episodes and spells used for the econometric analysis. **%MISS** and **%SPEC** indicate the percentage of missing episodes and the percentage of episodes with specialised care markers.

| procode3 | Hospital Name | totactivity | norefcost | finalepi | finalspell | % MISS | % SPEC |
|------------|---|-------------|-----------|----------|------------|--------|----------------|
| RR1 | Heart of England NHS Foundation Trust | | 23,410 | 283,258 | 250,038 | 7.65 | 28.04 |
| RHQ | Sheffield Teaching Hospitals NHS Foundation Trust | 297,715 | 37,869 | 259,812 | 238,867 | 12.73 | 44.61 |
| RWE | University Hospitals of Leicester NHS Trust | 267,803 | 27,009 | 240,791 | 208,738 | 10.09 | 11.97 |
| RR8 | Leeds Teaching Hospitals NHS Trust | 257,225 | 23,209 | 232,903 | 205,721 | 9.46 | 13.98 |
| RW6 | Pennine Acute Hospitals NHS Trust | 245,134 | 24,616 | 220,305 | 197,757 | 10.13 | 5.42 |
| RX1 | Nottingham University Hospitals NHS Trust | 221,639 | 34,608 | 186,049 | 162,883 | 16.06 | 13.00 |
| RM1 | Norfolk and Norwich University Hospital NHS Trust | 217,319 | 24,134 | 193,017 | 169,225 | 11.18 | 23.53 |
| RTH | Oxford Radcliffe Hospitals NHS Trust | 216,582 | 14,036 | 202,545 | 190,223 | 6.48 | 36.42 |
| RXN | Lancashire Teaching Hospitals NHS Foundation Trust | 210,031 | 34,078 | 175,816 | 165,898 | 16.29 | 6.40 |
| RTE | Gloucestershire Hospitals NHS Foundation Trust | 206,097 | 48,664 | 157,373 | 138,514 | 23.64 | 4.80 |
| RJE | University Hospital of North Staffordshire NHS Trust | 202,646 | 15,084 | 187,312 | 167,766 | 7.57 | 16.41 |
| RTD RJ1 | The Newcastle Upon Tyne Hospitals NHS Foundation Trust | 201,320 | 31,149 | 169,545 | 158,189 | 15.78 | 15.07 13.36 |
| | Guy's and St Thomas' NHS Foundation Trust | 199,824 | 11,696 | 187,820 | 180,341 | 6.01 | |
| RVJ | North Bristol NHS Trust | 188,638 | 4,860 | 183,475 | 171,464 | 2.74 | 40.64 |
| RW3 | Central Manchester and Manchester Children's University Hospitals NHS Trust | 184,726 | 15,574 | 169,071 | 153,979 | 8.47 | 40.85 |
| RAL | Royal Free Hampstead NHS Trust | 183,398 | 90,998 | 90,792 | 81,666 | 50.49 | 9.95 |
| RGT | Cambridge University Hospitals NHS Foundation Trust | 183,327 | 60,823 | 122,437 | 114,937 | 33.21 | 13.96 |
| RYJ | Imperial College Healthcare NHS Trust | 183,307 | 26,395 | 156,802 | 142,066 | 14.46 | 13.65 |
| RYQ | South London Healthcare NHS Trust | 175,337 | 12,194 | 162,733 | 150,014 | 7.19 | 4.52 |
| RTG | Derby Hospitals NHS Foundation Trust | 174,860 | 18,580 | 156,269 | 133,093 | 10.63 | 5.61 |
| RWD | United Lincolnshire Hospitals NHS Trust | 172,582 | 16,647 | 155,675 | 136,247 | 9.80 | 4.33 |
| RWA | Hull and East Yorkshire Hospitals NHS Trust | 171,457 | 10,070 | 161,250 | 138,984 | 5.95 | 10.45 |
| RTR | South Tees Hospitals NHS Trust | 163,455 | 24,016 | 139,426 | 118,578 | 14.70 | 10.97 |
| RHU | Portsmouth Hospitals NHS Trust | 162,693 | 24,310 | 137,466 | 118,261 | 15.51 | 6.67 |
| RXF | Mid Yorkshire Hospitals NHS Trust | 158,609 | 9,087 | 149,522 | 129,702 | 5.73 | 4.15 |
| RH8 | Royal Devon and Exeter NHS Foundation Trust | 157,081 | 13,214 | 143,211 | 120,320 | 8.83 | 13.39 |
| RVV | East Kent Hospitals NHS Trust | 155,994 | 20,966 | 132,610 | 124,896 | 14.99 | 5.89 |
| REF | Royal Cornwall Hospitals NHS Trust | 155,785 | 15,660 | 140,087 | 121,770 | 10.08 | 8.41 |

| procode3 | Hospital Name | totactivity | norefcost | finalepi | finalspell | % MISS | % SPEC |
|----------|---|-------------|-----------|----------|------------|--------|--------|
| RHM | Southampton University Hospitals NHS Trust | 154,564 | 14,015 | 140,390 | 113,195 | 9.17 | 18.51 |
| RF4 | Barking, Havering and Redbridge Hospitals NHS Trust | | 16,922 | 137,173 | 118,376 | 10.99 | 5.08 |
| RXK | Sandwell and West Birmingham Hospitals NHS Trust | 153,787 | 12,097 | 141,688 | 126,597 | 7.87 | 4.69 |
| RA7 | United Bristol Healthcare NHS Trust | 149,437 | 21,943 | 126,756 | 109,364 | 15.18 | 20.53 |
| RKB | University Hospitals Coventry and Warwickshire NHS Trust | 148,717 | 13,878 | 134,788 | 117,514 | 9.37 | 9.10 |
| RXR | East Lancashire Hospitals NHS Trust | 144,248 | 18,102 | 126,146 | 111,334 | 12.55 | 3.81 |
| RXP | County Durham and Darlington NHS Foundation Trust | 139,859 | 6,820 | 133,038 | 118,895 | 4.88 | 3.83 |
| RNA | Dudley Group of Hospitals NHS Trust | 136,450 | 26,609 | 109,783 | 98,713 | 19.54 | 8.29 |
| RLN | City Hospitals Sunderland NHS Foundation Trust | 135,553 | 18,762 | 116,791 | 102,281 | 13.84 | 5.76 |
| RTF | Northumbria Healthcare NHS Foundation Trust | 134,105 | 14,130 | 119,945 | 102,856 | 10.56 | 3.81 |
| RM3 | Salford Royal NHS Foundation Trust | 132,649 | 48,480 | 83,871 | 72,445 | 36.77 | 7.30 |
| RHW | Royal Berkshire NHS Foundation Trust | 132,345 | 8,801 | 123,544 | 120,564 | 6.65 | 35.23 |
| RL4 | The Royal Wolverhampton Hospitals NHS Trust | 131,927 | 18,392 | 113,507 | 102,254 | 13.96 | 16.77 |
| RQ6 | Royal Liverpool and Broadgreen University Hospitals NHS Trust | 131,740 | 8,985 | 122,755 | 107,476 | 6.82 | 13.59 |
| RK9 | Plymouth Hospitals NHS Trust | 131,563 | 11,210 | 120,251 | 106,152 | 8.60 | 11.26 |
| RJZ | King's College Hospital NHS Foundation Trust | 130,211 | 21,753 | 101,609 | 90,596 | 21.97 | 25.21 |
| RYR | Western Sussex Hospitals NHS Trust | 128,301 | 8,842 | 119,170 | 106,965 | 7.12 | 4.67 |
| RVL | Barnet and Chase Farm Hospitals NHS Trust | 126,442 | 18,341 | 107,724 | 95,522 | 14.80 | 5.71 |
| RDZ | The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust | 126,373 | 23,934 | 102,236 | 83,507 | 19.10 | 2.87 |
| RXW | Shrewsbury and Telford Hospital NHS Trust | 125,974 | 14,871 | 111,103 | 99,258 | 11.80 | 15.25 |
| RWY | Calderdale and Huddersfield NHS Foundation Trust | 123,799 | 10,204 | 113,429 | 100,545 | 8.38 | 4.26 |
| REM | Aintree University Hospitals NHS Foundation Trust | 123,542 | 10,063 | 113,193 | 89,699 | 8.38 | 23.53 |
| RRK | University Hospital Birmingham NHS Foundation Trust | 122,971 | 8,288 | 114,675 | 105,630 | 6.75 | 36.73 |
| RP5 | Doncaster and Bassetlaw Hospitals NHS Foundation Trust | 122,479 | 9,485 | 112,992 | 101,020 | 7.75 | 4.85 |
| RJ7 | St George's Healthcare NHS Trust | 118,887 | 11,285 | 107,292 | 103,192 | 9.75 | 13.09 |
| RWP | Worcestershire Acute Hospitals NHS Trust | 118,010 | 13,047 | 104,955 | 97,144 | 11.06 | 3.91 |
| RXL | Blackpool, Fylde and Wyre Hospitals NHS Foundation Trust | 117,989 | 9,616 | 107,792 | 91,881 | 8.64 | 9.89 |
| RAE | Bradford Teaching Hospitals NHS Foundation Trust | 117,687 | 7,970 | 109,536 | 101,829 | 6.93 | 5.27 |
| RRV | University College London Hospitals NHS Foundation Trust | 115,293 | 14,568 | 100,554 | 95,633 | 12.78 | 17.06 |
| RBL | Wirral University Teaching Hospital NHS Foundation Trust | 112,525 | 8,940 | 103,560 | 89,657 | 7.97 | 3.52 |

| procode3 | Hospital Name | totactivity | norefcost | finalepi | finalspell | % MISS | % SPEC |
|----------|---|-------------|-----------|----------|------------|--------|--------|
| RXH | Brighton and Sussex University Hospitals NHS Trust | 110,739 | 3,381 | 107,301 | 95,393 | 3.10 | 10.30 |
| RWH | East and North Hertfordshire NHS Trust | 110,530 | 8,755 | 100,823 | 89,528 | 8.78 | 4.46 |
| RTX | University Hospitals of Morecambe Bay NHS Trust | 109,052 | 14,061 | 94,911 | 86,381 | 12.97 | 4.53 |
| RJL | Northern Lincolnshire and Goole Hospitals NHS Foundation Trust | 108,267 | 25,142 | 83,117 | 72,775 | 23.23 | 5.86 |
| RNJ | Barts and The London NHS Trust | 107,558 | 33,715 | 72,547 | 71,240 | 32.55 | 23.38 |
| RV8 | North West London Hospitals NHS Trust | 107,009 | 15,421 | 91,531 | 82,549 | 14.46 | 4.22 |
| RXC | East Sussex Hospitals NHS Trust | 106,409 | 8,207 | 98,186 | 89,502 | 7.73 | 5.63 |
| RQ8 | Mid Essex Hospital Services NHS Trust | 106,207 | 11,146 | 95,061 | 84,546 | 10.49 | 5.26 |
| RDD | Basildon and Thurrock University Hospitals NHS Foundation Trust | 105,718 | 24,582 | 81,037 | 69,026 | 23.35 | 10.18 |
| RBN | St Helens and Knowsley Hospitals NHS Trust | 104,510 | 32,007 | 72,499 | 61,916 | 30.63 | 2.00 |
| RWF | Maidstone and Tunbridge Wells NHS Trust | 100,757 | 12,622 | 88,135 | 81,321 | 12.53 | 6.00 |
| RVR | Epsom and St Helier University Hospitals NHS Trust | 99,896 | 10,984 | 88,811 | 78,629 | 11.10 | 6.07 |
| RNS | Northampton General Hospital NHS Trust | 98,636 | 12,350 | 86,286 | 77,805 | 12.52 | 6.18 |
| RDE | Essex Rivers Healthcare NHS Trust | 98,523 | 19,199 | 79,098 | 65,866 | 19.72 | 4.11 |
| RAJ | Southend University Hospital NHS Foundation Trust | 96,533 | 30,837 | 65,696 | 61,164 | 31.94 | 4.11 |
| RVW | North Tees and Hartlepool NHS Foundation Trust | 96,358 | 8,049 | 88,309 | 74,998 | 8.35 | 2.66 |
| RXQ | Buckinghamshire Hospitals NHS Trust | 95,159 | 8,518 | 85,872 | 80,538 | 9.76 | 4.76 |
| RDU | Frimley Park Hospital NHS Foundation Trust | 94,091 | 7,390 | 86,699 | 75,881 | 7.86 | 3.86 |
| RGN | Peterborough and Stamford Hospitals NHS Foundation Trust | 93,019 | 10,649 | 82,366 | 71,552 | 11.45 | 5.45 |
| RNL | North Cumbria Acute Hospitals NHS Trust | 92,816 | 6,355 | 86,461 | 78,268 | 6.85 | 7.82 |
| RK5 | Sherwood Forest Hospitals NHS Foundation Trust | 92,793 | 43,012 | 49,745 | 47,179 | 46.39 | 3.45 |
| RGQ | Ipswich Hospital NHS Trust | 92,126 | 12,969 | 79,117 | 67,677 | 14.12 | 5.38 |
| RWJ | Stockport NHS Foundation Trust | 91,509 | 12,413 | 79,083 | 75,421 | 13.58 | 3.51 |
| RWW | North Cheshire Hospitals NHS Trust | 91,279 | 5,227 | 86,052 | 74,482 | 5.73 | 4.26 |
| RRF | Wrightington, Wigan and Leigh NHS Trust | 90,698 | 1,346 | 89,269 | 77,178 | 1.58 | 5.56 |
| RWG | West Hertfordshire Hospitals NHS Trust | 90,560 | 4,206 | 86,030 | 76,236 | 5.00 | 5.58 |
| RM2 | University Hospital of South Manchester NHS Foundation Trust | 90,239 | 26,453 | 63,721 | 60,013 | 29.39 | 13.43 |
| RD7 | Heatherwood and Wexham Park Hospitals NHS Foundation Trust | 89,430 | 17,165 | 72,265 | 61,416 | 19.19 | 5.15 |
| RN3 | Swindon and Marlborough NHS Trust | 88,792 | 6,543 | 82,177 | 70,710 | 7.45 | 5.87 |
| RCB | York Hospitals NHS Foundation Trust | 87,571 | 3,498 | 83,774 | 73,717 | 4.34 | 4.61 |

| procode3 | Hospital Name | totactivity | norefcost | finalepi | finalspell | % MISS | % SPEC |
|----------|---|-------------|-----------|----------|------------|--------|--------|
| RD3 | Poole Hospital NHS Foundation Trust | 86,093 | 9,745 | 76,325 | 67,614 | 11.35 | 5.67 |
| RC9 | Luton and Dunstable Hospital NHS Foundation Trust | 85,284 | 5,719 | 79,223 | 67,503 | 7.11 | 6.76 |
| RGC | Whipps Cross University Hospital NHS Trust | 84,498 | 8,017 | 76,480 | 69,458 | 9.49 | 5.34 |
| RBA | Taunton and Somerset NHS Foundation Trust | 84,387 | 12,017 | 72,370 | 65,144 | 14.24 | 5.64 |
| RGP | James Paget University Hospitals NHS Foundation Trust | 84,194 | 23,244 | 60,950 | 53,362 | 27.61 | 4.24 |
| RBD | Dorset County Hospital NHS Foundation Trust | 83,767 | 6,230 | 77,537 | 72,115 | 7.44 | 10.31 |
| RBT | Mid Cheshire Hospitals NHS Trust | 83,383 | 5,968 | 76,777 | 64,959 | 7.92 | 2.34 |
| RMC | Bolton Hospitals NHS Trust | 81,271 | 3,749 | 77,397 | 69,944 | 4.77 | 5.03 |
| RPA | Medway NHS Trust | 78,936 | 11,955 | 66,762 | 59,397 | 15.42 | 4.21 |
| RD1 | Royal United Hospital Bath NHS Trust | 78,089 | 2,891 | 75,115 | 65,188 | 3.81 | 6.25 |
| RNQ | Kettering General Hospital NHS Trust | 78,067 | 4,100 | 73,966 | 65,938 | 5.25 | 5.65 |
| RCX | The Queen Elizabeth Hospital King's Lynn NHS Trust | 78,021 | 5,341 | 72,680 | 62,166 | 6.85 | 4.03 |
| RFR | The Rotherham NHS Foundation Trust | 77,929 | 3,001 | 74,908 | 71,690 | 3.88 | 4.97 |
| RJR | Countess of Chester Hospital NHS Foundation Trust | 77,873 | 14,195 | 63,668 | 54,593 | 18.24 | 4.02 |
| RFS | Chesterfield Royal Hospital NHS Foundation Trust | 77,856 | 8,251 | 69,592 | 62,471 | 10.61 | 4.70 |
| RTK | Ashford and St Peter's Hospitals NHS Trust | 76,917 | 19,201 | 57,705 | 54,980 | 24.98 | 5.59 |
| RTP | Surrey and Sussex Healthcare NHS Trust | 76,289 | 4,756 | 71,338 | 64,308 | 6.49 | 4.22 |
| RJ6 | Mayday Healthcare NHS Trust | 76,062 | 17,555 | 58,358 | 51,999 | 23.28 | 4.90 |
| RA9 | South Devon Healthcare NHS Foundation Trust | 76,018 | 5,631 | 70,387 | 59,770 | 7.41 | 7.00 |
| RAX | Kingston Hospital NHS Trust | 75,735 | 6,400 | 69,137 | 58,671 | 8.71 | 4.45 |
| RQM | Chelsea and Westminster Hospital NHS Foundation Trust | 73,612 | 22,465 | 50,976 | 48,130 | 30.75 | 8.94 |
| RFF | Barnsley Hospital NHS Foundation Trust | 72,290 | 8,314 | 63,915 | 54,122 | 11.59 | 5.33 |
| RA2 | Royal Surrey County Hospital NHS Trust | 72,268 | 7,199 | 64,905 | 59,136 | 10.19 | 9.01 |
| RNZ | Salisbury NHS Foundation Trust | 70,013 | 11,582 | 58,328 | 52,877 | 16.69 | 7.28 |
| RD8 | Milton Keynes Hospital NHS Foundation Trust | 67,913 | 18,577 | 49,302 | 42,685 | 27.40 | 4.23 |
| RJD | Mid Staffordshire NHS Foundation Trust | 67,644 | 5,927 | 61,717 | 56,492 | 8.76 | 4.19 |
| RBK | Walsall Hospitals NHS Trust | 64,866 | 9,180 | 55,589 | 48,058 | 14.30 | 7.44 |
| RNH | Newham University Hospital NHS Trust | 64,738 | 6,478 | 58,260 | 53,115 | 10.01 | 1.59 |
| RQW | The Princess Alexandra Hospital NHS Trust | 64,080 | 5,778 | 58,163 | 55,201 | 9.23 | 5.87 |
| RVY | Southport and Ormskirk Hospital NHS Trust | 63,471 | 1,797 | 61,646 | 54,926 | 2.88 | 4.05 |

| procode3 | Hospital Name | totactivity | norefcost | finalepi | finalspell | % MISS | % SPEC |
|----------|--|-------------|-----------|----------|------------|--------|--------|
| RGR | West Suffolk Hospitals NHS Trust | 63,242 | 8,309 | 54,933 | 47,546 | 13.14 | 4.57 |
| RJ2 | The Lewisham Hospital NHS Trust | 59,122 | 11,198 | 47,848 | 45,320 | 19.07 | 7.30 |
| RMP | Tameside Hospital NHS Foundation Trust | 58,050 | 1,391 | 56,648 | 49,679 | 2.42 | 3.22 |
| RCF | Airedale NHS Trust | 57,362 | 5,197 | 52,147 | 45,489 | 9.09 | 3.74 |
| RJC | South Warwickshire General Hospitals NHS Trust | 55,073 | 3,212 | 51,861 | 46,827 | 5.83 | 4.12 |
| RAS | The Hillingdon Hospital NHS Trust | 54,496 | 4,425 | 50,041 | 47,786 | 8.17 | 2.87 |
| RN5 | Basingstoke and North Hampshire NHS Foundation Trust | 54,441 | 3,859 | 50,534 | 45,956 | 7.18 | 3.88 |
| RN7 | Dartford and Gravesham NHS Trust | 54,147 | 11,065 | 43,058 | 39,113 | 20.48 | 3.05 |
| RJF | Burton Hospitals NHS Trust | 54,115 | 6,598 | 47,517 | 42,873 | 12.19 | 3.61 |
| RBZ | Northern Devon Healthcare NHS Trust | 53,831 | 3,836 | 49,966 | 40,255 | 7.18 | 5.15 |
| RAP | North Middlesex University Hospital NHS Trust | 53,669 | 7,191 | 46,419 | 35,715 | 13.51 | 3.59 |
| RQX | Homerton University Hospital NHS Foundation Trust | 52,174 | 4,358 | 47,562 | 42,805 | 8.84 | 4.43 |
| RFW | West Middlesex University Hospital NHS Trust | 51,550 | 5,134 | 46,410 | 38,903 | 9.97 | 5.26 |
| RN1 | Winchester and Eastleigh Healthcare NHS Trust | 51,503 | 8,999 | 42,390 | 37,113 | 17.69 | 4.51 |
| RC1 | Bedford Hospital NHS Trust | 51,497 | 8,157 | 43,257 | 39,143 | 16.00 | 6.23 |
| RPY | The Royal Marsden NHS Foundation Trust | 51,482 | 1,329 | 50,103 | 50,103 | 2.68 | 6.42 |
| RKE | The Whittington Hospital NHS Trust | 51,189 | 4,535 | 46,654 | 42,413 | 8.86 | 7.70 |
| RCC | Scarborough and North East Yorkshire Health Care NHS Trust | 48,161 | 3,598 | 44,558 | 39,934 | 7.48 | 3.09 |
| RBS | Royal Liverpool Children's NHS Trust | 47,033 | 7,116 | 39,913 | 35,265 | 15.14 | 32.43 |
| RR7 | Gateshead Health NHS Foundation Trust | 46,978 | 3,027 | 43,951 | 37,444 | 6.44 | 2.24 |
| RCD | Harrogate and District NHS Foundation Trust | 46,008 | 2,282 | 43,659 | 42,161 | 5.11 | 3.66 |
| RA4 | Yeovil District Hospital NHS Foundation Trust | 45,977 | 3,310 | 42,204 | 34,619 | 8.21 | 4.78 |
| RC3 | Ealing Hospital NHS Trust | 45,900 | 1,458 | 44,442 | 39,577 | 3.18 | 3.03 |
| RLT | George Eliot Hospital NHS Trust | 43,694 | 3,611 | 40,083 | 36,600 | 8.26 | 4.78 |
| RJN | East Cheshire NHS Trust | 42,061 | 4,743 | 37,318 | 33,596 | 11.28 | 3.37 |
| RE9 | South Tyneside NHS Foundation Trust | 40,365 | 3,423 | 36,938 | 31,108 | 8.49 | 3.71 |
| RQQ | Hinchingbrooke Health Care NHS Trust | 37,751 | 2,310 | 35,441 | 32,047 | 6.12 | 5.97 |
| RA3 | Weston Area Health NHS Trust | 37,582 | 4,234 | 33,096 | 27,935 | 11.94 | 3.38 |
| RLQ | Hereford Hospitals NHS Trust | 37,305 | 1,721 | 35,570 | 31,536 | 4.65 | 4.99 |
| RQ3 | Birmingham Children's Hospital NHS Foundation Trust | 35,660 | 3,159 | 32,464 | 31,368 | 8.96 | 49.59 |

| procode3 | Hospital Name | totactivity | norefcost | finalepi | finalspell | % MISS | % SPEC |
|----------|---|-------------|-----------|----------|------------|--------|--------|
| RP4 | Great Ormond Street Hospital For Children NHS Trust | | 5,197 | 28,549 | 26,041 | 15.40 | 71.42 |
| RT3 | Royal Brompton and Harefield NHS Trust | 32,282 | 4,458 | 27,575 | 25,901 | 14.58 | 55.92 |
| RM4 | Trafford Healthcare NHS Trust | 31,683 | 2,183 | 29,500 | 26,163 | 6.89 | 6.09 |
| REP | Liverpool Women's NHS Foundation Trust | 29,012 | 638 | 28,374 | 28,351 | 2.20 | 0.62 |
| RP6 | Moorfields Eye Hospital NHS Foundation Trust | 27,388 | 1,561 | 25,817 | 25,817 | 5.74 | 6.91 |
| RCU | Sheffield Children's NHS Foundation Trust | 26,358 | 2,420 | 23,928 | 22,821 | 9.22 | 39.06 |
| RGM | Papworth Hospital NHS Foundation Trust | 22,437 | 4,402 | 18,035 | 17,665 | 19.62 | 62.49 |
| RBV | Christie Hospital NHS Foundation Trust | 22,424 | 4,274 | 18,145 | 17,945 | 19.08 | 21.47 |
| RPC | Queen Victoria Hospital NHS Foundation Trust | 18,725 | 1,121 | 17,598 | 17,567 | 6.02 | 11.68 |
| RLU | Birmingham Women's NHS Foundation Trust | 17,840 | 2,413 | 15,427 | 14,830 | 13.53 | 1.49 |
| RRJ | The Royal Orthopaedic Hospital NHS Foundation Trust | 15,541 | 68 | 15,473 | 15,473 | 0.44 | 10.58 |
| RET | Walton Centre for Neurology and Neurosurgery NHS Trust | 11,830 | 5,643 | 6,130 | 6,060 | 48.18 | 22.99 |
| RAN | Royal National Orthopaedic Hospital NHS Trust | 11,203 | 54 | 11,142 | 11,130 | 0.54 | 20.49 |
| RBQ | The Cardiothoracic Centre - Liverpool NHS Trust | 11,018 | 341 | 10,676 | 10,212 | 3.10 | 58.53 |
| RL1 | Robert Jones and Agnes Hunt Orthopaedic and District Hospital NHS Trust | 10,942 | 921 | 10,011 | 9,990 | 8.51 | 5.94 |
| RBF | Nuffield Orthopaedic Centre NHS Trust | 9,881 | 457 | 9,424 | 9,372 | 4.63 | 4.02 |
| REN | Clatterbridge Centre for Oncology NHS Foundation Trust | 4,264 | 986 | 3,190 | 3,182 | 25.19 | 8.36 |
| RBB | Royal National Hospital for Rheumatic Diseases NHS Foundation Trust | 3,576 | 91 | 3,485 | 3,485 | 2.54 | 0.11 |

Table 12: Equation 4 full results, OLS

| | 2008-2009 | 2009-2010 | | 2008-2009 | 2009-2010 |
|---------------------|------------|-----------------------|--------------|------------|-----------------------|
| | | | | b/signif | |
| Company | b/signif | b/signif 0.243 *** | ala a ai t | 0.013 | b/signif 0.041 *** |
| Cancer BMT | 0.186 *** | | obesity | 0.013 | 0.030 *** |
| | -0.089 | -0.293 ** | allergy | | |
| Haemophilia | -0.200 * | -0.232 ** | diabetes | -0.008 | 0.001 |
| Womens | -0.016 | 0.056 | hypertens | 0.047 | -0.012 |
| Spinal | 0.269 *** | -0.119 | haemorr | 0.081 ** | 0.088 *** |
| Neurosciences | 0.167 *** | 0.108 | histdis | 0.020 * | 0.021 ** |
| Cystic fibrosis | 0.330 *** | 0.283 *** | riskfact | 0.001 | -0.004 |
| Renal | -0.086 | 0.199 | congmalf | 0.051 *** | 0.033 |
| Intestinal failure | -0.019 | -0.004 | risk_phys | -0.007 | 0.045 |
| Cardiology | -0.059 | -0.049 | risk_psysoc | 0.192 *** | 0.164 *** |
| Cleft lip | -0.014 | 0.047 | tr_in_el | 0.008 | -0.061 |
| Infectious diseases | 0.202 *** | 0.355 *** | tr_in_nonel | 0.160 ** | 0.235 *** |
| Liver | 0.063 | -0.021 | tr_out_el | 0.140 *** | 0.132 *** |
| Children | 0.172 *** | 0.183 *** | tr_out_nonel | 0.129 *** | 0.110 *** |
| Dermatology | -0.004 | -0.013 | die | 0.072 *** | 0.068 *** |
| Rheumatology | 0.160 *** | 0.127 * | emerg | -0.013 | -0.017 |
| Endocrinology | 0.011 | 0.008 | episodes | 0.108 *** | 0.116 *** |
| Respiratory | -0.073 | -0.041 | dreg2 | 0.115 | -0.035 |
| Vascular diseases | 0.173 ** | 0.194 * | dreg3 | 0.160 *** | 0.065 |
| Pain Management | 0.217 | 2.168 *** | dreg4 | 0.022 | -0.015 |
| Ear surgery | 0.018 | -0.088 | dreg5 | 0.009 | -0.041 |
| Colorectal | 0.212 *** | 0.119 *** | dreg6 | 0.068 | -0.021 |
| Orthopaedic | 0.222 *** | 0.007 | dreg7 | 0.007 | -0.069 |
| Morbid obesity | -0.010 | -0.074 | dreg8 | 0.044 | 0.050 |
| Metabolic disorders | 0.002 | 0.323 | dreg9 | 0.055 | -0.004 |
| Ophthalmology | 0.077 | 0.080 | urban1 | -0.003 | 0.002 |
| Haemoglobinopathy | 0.013 | 0.069 | white1 | 0.015 ** | -0.002 |
| imd04c | 0.000 | -0.004 | female1 | 0.599 | 0.184 |
| imd04ed | 0.000 | 0.000 | male1 | 0.600 | 0.179 |
| imd04hd | -0.009 | 0.002 | age | 0.085 | 0.000 |
| imd04hs | 0.000 | 0.000 | age2 | -0.002 | 0.000 |
| imd04i | 0.090 ** | 0.042 | age3 | 0.000 * | 0.000 |
| imd04ia | -0.047 * | 0.053 | femage | -0.086 | -0.002 |
| imd04ic | -0.078 *** | -0.050 | femage2 | 0.002 | 0.000 |
| imd04le | 0.000 | 0.000 | femage3 | 0.000 * | 0.000 |
| imd04rk | 0.000 *** | 0.000 | malage | -0.087 | -0.003 |
| pregnancy | 0.079 *** | 0.077 *** | malage2 | 0.002 | 0.000 |
| drug | -0.001 | 0.001 | malage3 | 0.002 | 0.000 |
| alcohol | -0.041 *** | -0.036 *** | _cons | 0.260 | 0.689 *** |
| smoke | -0.008 | -0.009 | N N | 12,154,599 | 12,971,384 |
| SHIOKC | -0.000 | * 100/ | 1.1 | 14,101,077 | 14,7/1,007 |

Notes: Significance level: *** 1%, ** 5%, * 10%.

Table 13: Equation 4 full results, GLM

| | 2000 2000 | 2000 2010 | | 2000 2000 | 2000 2010 |
|---------------------|------------|------------|--------------|-----------|------------|
| | 2008-2009 | 2009-2010 | | 2008-2009 | 2009-2010 |
| 2 | b/signif | b/signif | 1 | b/signif | b/signif |
| Cancer | 0.194 *** | 0.268 *** | obesity | 0.026 | 0.055 *** |
| BMT | -0.025 | -0.034 | allergy | 0.024 ** | 0.030 *** |
| Haemophilia | -0.163 | -0.220 | diabetes | -0.018 | 0.000 |
| Womens | -0.002 | 0.062 | hypertens | 0.056 | -0.022 ** |
| Spinal | 0.257 *** | 0.126 * | haemorr | 0.071 ** | 0.082 *** |
| Neurosciences | 0.187 *** | 0.184 *** | histdis | 0.020 | 0.036 *** |
| Cystic fibrosis | 0.290 *** | 0.255 *** | riskfact | -0.012 | -0.003 |
| Renal | -0.091 | 0.216 | congmalf | 0.058 *** | 0.045 ** |
| Intestinal failure | -0.023 | -0.010 | risk_phys | 0.004 | 0.065 ** |
| Cardiology | 0.059 * | 0.058 | risk_psysoc | 0.175 *** | 0.162 *** |
| Cleft lip | 0.003 | 0.049 | tr_in_el | 0.012 | -0.004 |
| Infectious diseases | 0.183 *** | 0.290 *** | tr_in_nonel | 0.157 *** | 0.174 *** |
| Liver | 0.075 | 0.084 ** | tr_out_el | 0.122 *** | 0.117 *** |
| Children | 0.216 *** | 0.212 *** | tr_out_nonel | 0.129 *** | 0.118 *** |
| Dermatology | 0.016 | -0.012 | die | 0.073 *** | 0.072 *** |
| Rheumatology | 0.197 *** | 0.292 *** | emerg | -0.023 | -0.033 * |
| Endocrinology | 0.050 | 0.065 | episodes | 0.106 *** | 0.116 *** |
| Respiratory | -0.012 | 0.012 | dreg2 | 0.109 | -0.039 |
| Vascular diseases | 0.164 *** | 0.241 *** | dreg3 | 0.14 *** | 0.053 |
| Pain Management | 0.209 | 1.226 *** | dreg4 | 0.033 | 0.016 |
| Ear surgery | 0.084 | 0.099 | dreg5 | -0.017 | -0.069 |
| Colorectal | 0.200 *** | 0.125 *** | dreg6 | 0.081 * | 0.011 |
| Orthopaedic | 0.227 *** | 0.158 *** | dreg7 | -0.021 | -0.104 * |
| Morbid obesity | -0.042 | -0.109 | dreg8 | 0.03 | 0.003 |
| Metabolic disorders | 0.025 | 0.342 | dreg9 | 0.08 ** | 0.033 |
| Ophthalmology | 0.095 | 0.081 | urban1 | 0.005 | 0.011 |
| Haemoglobinopathy | 0.002 | 0.073 | white1 | 0.008 | -0.011 |
| imd04c | 0.021 * | 0.007 | female1 | 0.431 * | 0.063 |
| imd04ed | 0.000 | 0.000 | male1 | 0.434 * | 0.056 |
| imd04hd | -0.022 | 0.000 | age | 0.07 * | -0.015 |
| imd04hs | 0.001 | 0.000 | age2 | -0.002 ** | 0.000 |
| imd04i | -0.075 | -0.027 | age3 | 0 ** | 0.000 |
| imd04ia | 0.104 ** | 0.119 * | femage | -0.071 * | 0.014 |
| imd04ic | -0.014 | 0.025 | femage2 | 0.002 ** | 0.000 |
| imd04le | -0.001 * | 0.000 | femage3 | 0 ** | 0.000 |
| imd04rk | 0.000 | 0.000 | malage | -0.071 ** | 0.014 |
| pregnancy | 0.057 * | 0.053 ** | malage2 | 0.002 ** | 0.000 |
| drug | -0.009 | -0.012 | malage3 | 0.002 | 0.000 |
| alcohol | -0.051 *** | -0.049 *** | _cons | -0.63 *** | -0.240 |
| smoke | -0.005 | 0.002 | N | 12154599 | 12,971,384 |
| JIIIOKC | -0.003 | * 100/ | 117 | 14101077 | 14,7/1,JUT |

Notes: Significance level: *** 1%, ** 5%, * 10%.

Table 14: Variables label and definition

| Variable name | Description |
|--------------------------|--|
| imd04c | Index of Multiple Deprivation: Crime |
| imd04ed | Index of Multiple Deprivation: Education, Skills and training |
| imd04hd | Index of Multiple Deprivation: Health Deprivation and Disability |
| imd04hs | Index of Multiple Deprivation: Barriers to Housing and Services |
| imd04i | Index of Multiple Deprivation: Income deprivation |
| imd04ia | Index of Multiple Deprivation:Income Deprivation Affecting Older People |
| imd04ic | Index of Multiple Deprivation: Income Deprivation Affecting Children |
| imd04le | Index of Multiple Deprivation: Living Environment |
| imd04rk | Index of Multiple Deprivation: Overall ranking |
| pregnancy | =1, One of the patient diagnosis is: pregnancy,childbirth or puerperium |
| drug | =1, Patient is drug user or drug dependent |
| alcohol | =1, Patient is alcohol user or alcohol dependent |
| smoke | =1, Patient is tobacco user or tobacco dependent |
| obesity | =1, Patient with obesity problems |
| allergy | =1, Patient with personal history of allergy |
| diabetes | =1, Patient with personal history of allergy |
| hypertens | =1, Patient with hypertension problems |
| haemorr | =1, Patient with haemorrage/coagulation problems |
| histdis | =1, Patient with haemonage/coagulation problems =1, Patient with personal history of diseases |
| riskfact | =1, Patient with personal history of diseases |
| congmalf | =1, Patient with congenital malformations |
| | =1, Patient exposed to physical risk factors |
| risk_phys risk_psysoc | =1, Patient exposed to physical risk factors =1, Patient with problems related to psychosocial circumstances |
| tr in el | =1, Patient transferred from an eligible provider |
| tr in nonel | =1, Patient transferred from a non-eligible provider |
| tr_out_el | =1, Patient transferred from a non-engible provider |
| tr out nonel | =1, Patient transferred to an engible provider |
| die | =1, Patient died |
| | =1, Patient died =1, Patient admitted as emergency |
| emerg episodes | Number of episodes in the spell |
| East of England | =1, Region of treatment: East of England |
| London | =1, Region of treatment: Last of England =1, Region of treatment: London |
| North-East | =1, Region of treatment: North-East |
| North-West | =1, Region of treatment: North-West |
| South-East | =1, Region of treatment: North-West |
| South-West | =1, Region of treatment: South-East |
| West Midlands | |
| Yorkshire | =1, Region of treatment: West Midlands =1, Region of treatment: Yorkshire |
| urban1 | =1, Tregion of treatment. Forkshire |
| white1 | =1, Orban area =1, ethnicity is white |
| female1 | =1, Patient is female |
| | |
| male1 | =1, Patient is male |
| age | Patient age at the beginning of the spell |

| age2 | Squared patient age |
|---------|---------------------------------|
| age3 | Cubic power of patient age |
| femage | Interaction: Age*Female |
| femage2 | Interaction: Squared age*Female |
| femage3 | Interaction: Cubic age*Female |
| malage | Interaction: Age*Male |
| malage2 | Interaction: Squared age*Male |
| malage3 | Interaction: Cubic age*Male |